The Efficacy of 100 and 300 mg Gabapentin in the Treatment of Carpal Tunnel Syndrome

Bina Eftekharsadat, Arash Babaei-Ghazani, Afshin Habibzadeh, Bina Eftekharsadat, Arash Babaei-Ghazani, Afshin Habibzadeh

Abstract

Carpal tunnel syndrome (CTS) is a neuropathy due to the compression of the median nerve. It is shown that gabapentin in high doses is effective in treatment of CTS patients. In this study we evaluated the efficacy of low doses of gabapentin in treatment of CTS patients. Ninety patients with CTS were randomly assigned to groups A, B and C. Gabapentin was administered to group A with dose of 100 mg/day and to group B with dose of 300 mg/day for 2 months. Group C received no treatment. Before and after treatment, patients were evaluated using Visual analogue scale (VAS) for pain and parasthesia, Boston carpal tunnel questionnaire (BCTQ) including Symptom Severity Scale (SSS) and Functional Status Scale (FSS) to evaluate the efficacy of the treatment. The pinch and grip strength was also measured. There was significant improvement in VAS, grip strength, pinch strength, SSS, FSS and BCTQ score in all three groups (p < 0.05), but the changes in CMAP and SNAP was not significant. Groups A and B in comparison to group C had significantly better improvement in VAS, pinch strength, SSS, FSS and BCTQ total score (p < 0.05). There was significantly more improvement in pinch strength and SSS score in group B compared to group A (p < 0.05). Gabapentin in low doses is a useful drug in treatment of CTS symptoms with no side effects and intolerance. Gabapentin with dose of 300 mg/day is more effective than the dose of 100 mg/day.

Keywords: BCTQ; Carpal tunnel syndrome; Gabapentin; VAS.

References

    1. Aroori S, Spence RA. Carpal tunnel syndrome. Ulster. Med. J. . 2008;77:6–17.
    1. Eftekharsadat B, Kazem Shakouri S, Shimia M, Rahbar M, Ghojazadeh M, Reza Rashidi M, Hadi Faraji M. Effect of E. laciniata (L) ointment on mild and moderate carpal tunnel syndrome: a double-blind, randomized clinical trial. Phytother. Res. 2011;25:290–295.
    1. Bland JD, Weller P, Rudolfer S. Questionnaire tools for the diagnosis of carpal tunnel syndrome from the patient history. Muscle. Nerve. . 2011;44:757–762.
    1. Sharifi-Mollayousefi A, Yazdchi-Marandi M, Ayramlou H, Heidari P, Salavati A, Zarrintan S, Sharifi-Mollayousefi A. Assessment of body mass index and hand anthropometric measurements as independent risk factors for carpal tunnel syndrome. Folia. Morphol. . Warsz;67(2008):36–42.
    1. Keith MW, Masear V, Chung K, Maupin K, Andary M, Amadio PC, Barth RW, Watters WC 3rd, Goldberg MJ, Haralson RH 3rd, Turkelson CM, Wies JL. Diagnosis of carpal tunnel syndrome. J. Am. Acad. Orthop. Surg. . 2009;17:389–396.
    1. Talebi M, Andalib S, Bakhti S, Ayromlou H, Aghili A, Talebi A. Effect of vitamin b6 on clinical symptoms and electrodiagnostic results of patients with carpal tunnel syndrome. Adv. Pharm. Bull. . 2013;3:283–288.
    1. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12–weeks, randomised, double–blind, multicentre, placebo-controlled trial of flexible- and fixed dose regimens. Pain. . 2005;115:254–263.
    1. Strojek K, Flöter T, Balkenohl M, Xie F, Griesing T. Pregabalin in the management of chronic neuropathic pain (NeP): a novel evaluation of flexible and fixed dosing. J. Pain. . 2004;5:S59.
    1. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled study. JAMA. . 1998;280:1831–1836.
    1. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin in the treatment of post-herpetic neuralgia: a randomized controlled trial. JAMA. . 1998;280:1837–1842.
    1. Taverner D, Lisbona MP, Segalés N, Docampo E, Calvet J, Castro S, Benito P. Efficacy of gabapentin in the treatment of carpal tunnel syndrome. Med. Clin. . Barc;130:371–373.
    1. Duman I, Aydemir K, Ozgul A, Kalyon TA. Assessment of the efficacy of gabapentin in carpal tunnel syndrome. J. Clin. Rheumatol. . 2008;14:175–177.
    1. Erdemoglu AK. The efficacy and safety of gabapentin in carpal tunnel patients: open label trial. Neurol. India. . 2009;57:300–303.
    1. Hui AC, Wong SM, Leung HW, Man BL, Yu E, Wong LK. Gabapentin for the treatment of carpal tunnel syndrome: a randomized controlled trial. Eur. J. Neurol. . 2011;18:726–730.
    1. Practice parameter for carpal tunnel syndrome (summary statement): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1993;43:2406–2409.
    1. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J. Neurochem. . 2005;94:1131–1139.
    1. Panah Khahi M, Yaghooti AA, Marashi SH, Nadjafi A. Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. Singapore. Med. J. . 2011;52:879–882.
    1. Turan A, White PF, Karamanlioglu B, Pamukçu Z. Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia. Anesth. Analg. . 2007;104:97–101.
    1. Pandey CK, Sahay S, Gupta D, Ambesh SP, Singh RB, Raza M, Singh U, Singh PK. Preemptive gabapentin decreases postoperative pain after lumbar discoidectomy. Can. J. Anaesth. . 2004;51:986–989.
    1. Pandey CK, Priye S, Singh S, Singh U, Singh RB, Singh PK. Preemptive use of gabapentin significantly decreases postoperative pain and rescue analgesic requirements in laparoscopic cholecystectomy. Can. J. Anaesth. . 2004;51:358–363.
    1. Ahmadi M, Samadbeik M, Sadoughi F. Modeling of outpatient prescribing process in iran: a gateway toward electronic prescribing system. Iran J Pharm Res. . 2014;13:725–38.
    1. Davoodi SH, Hajimiresmaiel SJ, Ajami M, Mohseni-Bandpei A, Ayatollahi SA, Dowlatshahi K, Javedan G, Pazoki-Toroudi H. Caffeine treatment prevented from weight regain after calorie shifting diet induced weight loss. Iran J Pharm Res. . 2014;13:707–18.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe